🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Energy Sector SEC Filings — May 26, 2026

The four filings in the S&P 500 Energy stream for May 26, 2026, reveal a sector in transition, with corporate governance and structural changes dominating over operational updates. The most critical development is ExxonMobil's push to redomicile from Delaware to Texas, a move with significant governance and legal implications that will be voted on imminently. APA Corp's annual meeting showed strong shareholder support for management, though notable dissent on executive compensation (14% against) signals a need for closer scrutiny of pay practices. The inclusion of two non-energy entities—a SPAC (Hall Chadwick) and a royalty company (XOMA Royalty)—highlights the stream's broadening scope, with XOMA's high-stakes merger with Ligand Pharmaceuticals representing a material 9/10 event. Period-over-period data from Hall Chadwick shows a 26.6% decline in cash reserves (from $631K to $463K) as it burns capital in its pre-business combination phase, while interest income from its trust account grew to $1.84M in Q1 2026. Overall, the sector is exhibiting a mix of defensive governance moves and high-risk M&A catalysts, with no direct operational or insider trading signals from the energy majors in this batch.

3 high priority 1 medium 4 total filings
· daily

US Material Events SEC 8-K Filings — May 26, 2026

The 50 filings reveal a mixed landscape dominated by capital structure actions (debt offerings, credit facility amendments, equity raises) and corporate events (M&A, Chapter 11, executive changes). Notable themes include a surge in debt capital market activity (Ares Capital, Starwood Property, Encore Capital) signaling strong institutional appetite for yield, while several companies (Trinseo, World Acceptance) show financial distress. The energy sector sees a strategic Canadian entry by Northern Oil & Gas, while tech/biotech companies (Assembly Biosciences, Editas Medicine) pursue dilutive financings. Insider activity is limited, but executive departures (Cartesian CMO, SS Innovations CFO) raise governance concerns. Period-over-period comparisons are sparse, but covenant modifications and repeated note amendments (Odyssey Health) indicate liquidity pressures. Overall, the digest highlights a bifurcated market: well-capitalized firms accessing debt markets cheaply, while weaker players rely on dilutive equity or face restructuring.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 26, 2026

The 50 filings reveal a mixed landscape for Dow 30 constituents, with notable revenue growth at ARM Holdings (+23% YoY) and OPGEN (+481% YoY), offset by sharp declines at Veradigm (-5% YoY) and Barnwell Industries (-29% YoY). Insider activity is sparse but includes a significant CEO departure at SS Innovations and a CFO resignation at Sculptor. Forward-looking guidance was revised downward at Verra Mobility due to a major customer loss, while Ryan Specialty boosted its buyback authorization by $300M. Capital allocation trends show steady dividends at TriCo Bancshares and increased buyback capacity at Ryan Specialty. M&A activity includes Cogent's $225M data center sale and the Terra Quantum SPAC merger. Sentiment is generally neutral, with pockets of positive (Palomar board appointment, D-Wave funding) and negative (Verra Mobility, Nuvve delisting risk). Key themes include margin compression (ARM, Veradigm), revenue concentration risk (Verra Mobility, SOLV Energy), and governance concerns (Viking Therapeutics, Veritone).

20 high priority 30 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 26, 2026

The May 26, 2026 filings reveal a market dominated by capital markets activity (IPOs, debt issuances, buybacks) and regulatory milestones, with several high-conviction signals emerging. Key themes include a wave of SPAC and IPO filings (Quantinuum, Applied Aerospace, INNIO) with price ranges indicating strong demand, alongside significant M&A developments (GameStop's unsolicited eBay bid, Northern Oil & Gas's Canadian entry, Cumberland's asset sale). Period-over-period trends show mixed earnings quality: CSW Industrials grew revenue 23% YoY but saw operating margin contract 500 bps, while AutoZone's same-store sales rose 4.1% but gross margin fell 57 bps. Insider activity is limited but notable—Delta extended its lock-up on Wheels Up, signaling confidence. Risk flags center on going concern issues (Veritone, Global Interactive, TransCode) and regulatory non-compliance (Nuvve, Specificity). Opportunities arise from FDA appeal wins (Outlook Therapeutics), clinical catalysts (Editas, Cartesian), and strategic expansions (NOG, Ryan Specialty buyback). Overall, the digest points to a bifurcated market where growth is often costly, and investors must differentiate between sustainable outperformance and leveraged expansion.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 26, 2026

The 50 filings reveal a mixed picture for the S&P 500 Consumer Discretionary sector. Key themes include margin compression (AutoZone, Modine), insider selling (Veradigm), and regulatory catalysts (American Woodmark, Boxabl). AutoZone's 8.4% revenue growth was offset by a 57 bps gross margin decline, while Modine reported record sales (+47% YoY) but saw GAAP earnings fall 34% due to a pension charge. Veradigm's long-delayed filings showed a 5% revenue decline and a swing to a $292M loss. On the positive side, American Woodmark cleared FTC hurdles for its merger with MasterBrand, and Boxabl received Texas regulatory approval ahead of its SPAC merger. Capital allocation trends show increased reliance on dilutive financing (Future FinTech) and debt issuance (PNC, Ares Strategic Income Fund). Insider activity was limited, but notable CEO promotions (Medifast) and director appointments (Palomar) signal confidence. Overall, the sector faces headwinds from cost inflation and tariffs, but select companies with strong execution and catalysts offer opportunities.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 26, 2026

The 35 filings from the S&P 500 Healthcare sector reveal a sector bifurcated between high-risk, cash-burning biotechs and stable, capital-returning companies. A dominant theme is aggressive capital raising via dilutive offerings (Editas, Assembly Biosciences) to fund clinical milestones, contrasted with shareholder return programs (Ryan Specialty's $300M buyback increase). Insider sentiment is mixed, with significant shareholder dissent on executive compensation at Thermo Fisher (68.2% against say-on-pay) and Spruce Biosciences (38% against), signaling governance concerns. The most critical development is Editas Medicine's dual filing: positive preclinical data for EDIT-401 (90% LDL-C reduction) is overshadowed by a $125M dilutive offering and liver toxicity signals at higher doses, creating a high-risk/high-reward binary catalyst. Portfolio-level trends show a focus on gene editing and rare disease, with several companies (Pacira, Editas) defending or advancing IP estates, while others like Specificity face restatements and accounting failures. The sector presents a clear dichotomy: invest in established players with strong capital allocation or speculate on binary clinical catalysts with significant dilution risk.

11 high priority 24 medium 35 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 26, 2026

This intelligence stream analyzes 10 DEF 14A filings, revealing a stark bifurcation in the US small-cap and SPAC landscape. A dominant theme is existential distress: 4 of the 10 companies (Veritone, Origin Materials, Klotho Neurosciences, and multiple SPACs) are facing going-concern risks, liquidation, or Nasdaq non-compliance, with a combined materiality score of 8-10/10. This contrasts sharply with the operational strength of AZZ Inc., which reported record sales and profitability, a 40%+ share price increase, and a 39th consecutive year of profitability. The SPAC sector remains under severe pressure, with Bowen, Mountain Lake, and Pantages all seeking last-minute deadline extensions to avoid liquidation, highlighting a systemic failure to consummate deals. Insider activity is notably absent in most filings, but the unanimous board recommendations for dissolution at Origin Materials and the high insider ownership (70.3%) at Bowen voting for an extension provide critical signals. Period-over-period comparisons from AZZ show strong debt reduction ($385.3M) and shareholder returns ($43M in dividends/buybacks), while the distressed companies show deteriorating equity structures via reverse splits and massive share increases. The most actionable insights revolve around the binary outcomes of SPAC liquidations, the value-destructive nature of reverse splits, and the relative safe-haven of established industrial performers like AZZ.

10 high priority 10 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 26, 2026

The IPO pipeline is active with 9 filings on May 26, 2026, spanning diverse sectors including specialty chemicals (VARSAL TECH), biotech (Kardigan, GeoVax), solar construction (SOLV Energy), power solutions (Forgent), SPAC (Crestone), quantum computing via SPAC merger (SeeQC), space/defense (Firefly Aerospace), and a UK-based company (DPC Holdings). A key theme is the prevalence of mixed sentiment, with most issuers showing significant financial challenges: widening net losses (Kardigan's Q1 2026 loss tripled YoY), declining government revenue (GeoVax's Q1 2026 contract revenue dropped to $0), and material weaknesses in internal controls (VARSAL TECH). Insider activity is notably absent across all filings, suggesting limited management conviction at current valuations. Capital allocation is focused on R&D and expansion, with no dividends or buybacks. The most critical development is SeeQC's SPAC merger with a $65M PIPE, but execution risk exists as only 48.8% of warrant holders have consented (needs 65%). Sector themes reveal a bifurcation: capital-intensive industrial IPOs (VARSAL, SOLV, Forgent) carry high debt and customer concentration, while biotech IPOs (Kardigan, GeoVax) show escalating cash burn with no product revenue. The absence of insider buying and prevalence of net losses suggest investors should be highly selective, focusing on companies with clear catalysts like GeoVax's Phase 3 trial or Firefly's NASA contract.

9 high priority 9 total filings
· daily

Global High-Priority Regulatory Events — May 26, 2026

This digest covers 50 filings from May 26, 2026, revealing a market bifurcated between aggressive capital deployment (M&A, IPOs, debt raises) and deep distress (bankruptcies, insolvencies, going-concern warnings). A dominant theme is the quantum technology sector, where Terra Quantum AG is simultaneously in play with two SPACs (Axiom Intelligence and Mountain Lake), though exclusivity has expired on one, creating deal uncertainty. The energy sector shows strategic expansion, with Northern Oil & Gas entering Canada via a $259M Duvernay Shale acquisition, while APA Corp faces notable shareholder dissent (14% against say-on-pay). Credit markets are active, with Ares Capital upsizing its facility to $5.48B and Encore Capital issuing $750M in notes, signaling strong institutional liquidity. On the distress side, Trinseo PLC filed for Chapter 11 to reduce debt by $2B, wiping out equity, while multiple Indian companies (Kallam Textiles, Quadrant Televentures, Tricom Fruit Products) remain in insolvency proceedings. Several companies, including Veritone and Global Interactive Technologies, received going-concern warnings from auditors. The IPO pipeline is robust with 5 new filings (Quantinuum, Applied Aerospace, INNIO, Varsal Tech, ERock), though many are controlled companies or have material weaknesses. Insider activity was limited, but the most significant signal is Ryan Cohen's public proposal to acquire eBay for $125/share via GameStop, a highly unconventional move. Overall, the data suggests a 'risk-on' environment for institutional capital and strategic buyers, but acute risk for equity holders in over-levered or cash-burning entities.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 26, 2026

Financial results for the period show a mixed landscape: some companies achieved strong revenue growth (CSW Industrials +23%, Zscaler +25%, Digital Turbine +15%, OpGen +481%), but margin compression and widening losses are common themes. Five of thirteen filers reported net losses worsening year-over-year, with Kailera Therapeutics and Apimeds Pharmaceuticals seeing losses surge due to R&D and digital asset impairments, respectively. Cash positions are deteriorating across several small-cap names (T-REX, ConnectM, Hubilu), while Digital Turbine and Hubilu showed improved cash flow. No insider trading activity was reported in any filing. Forward-looking guidance was absent, but capital allocation trends indicate reinvestment in growth (Zscaler R&D +37%, Kailera R&D +602%) and debt management (Digital Turbine interest expense +68%). Sector disparities are evident: tech/software firms sustain growth with losses, healthcare/biotech face high cash burn, and industrials see margin pressure amid revenue gains.

13 high priority 13 total filings
· daily

US SEC Trading Suspension Halt Orders — May 26, 2026

Today's trading suspension stream reveals a bifurcated regulatory landscape: one company (P3 Health Partners) successfully exited the delisting gauntlet, while three others face mounting, multi-basis threats from Nasdaq. The most alarming pattern is the compounding of compliance failures—Nuvve and Vestand both face stacked violations (price + filing), creating a procedural death spiral where each new deficiency adds hearing complexity. Vestand stands out as the highest-risk name, having exhausted all exceptions and now relying on a 15-day stay. In contrast, Welsbach Technology Metals (EMAT) resolved its late filing within 24 hours, highlighting a critical distinction between administrative delay vs. systemic non-compliance. Across the four filings, zero insider buying was reported despite extreme distress, and no forward guidance was issued—both bearish signals suggesting management is either unable or unwilling to communicate. The key takeaway: the market should prepare for at least one imminent delisting (Vestand), and watch for a potential tidal wave of similar filing failures as Q1 2026 deadlines catch up with weak balance sheets.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 26, 2026

The 42 filings from May 26, 2026, paint a stark picture of a bifurcated US corporate landscape. While a handful of companies (Ares Capital, IREN, Allied Gaming) are executing large-scale, growth-oriented capital raises and acquisitions, a significant cohort is exhibiting classic distress signals. The most critical development is Trinseo PLC's Chapter 11 filing, which confirms a major restructuring in the chemicals sector and serves as a high-severity warning for other over-levered industrials. A secondary wave of distress is evident in the micro-cap and biotech space, with at least five companies (Nuvve, Vestand, TEN Holdings, World Acceptance, Future FinTech) receiving Nasdaq deficiency notices or requiring covenant relief, indicating systemic liquidity pressure. The dominant theme is a 'flight to quality' in capital markets, where well-capitalized firms easily access billions in credit (Ares, Encore Capital), while distressed entities are forced into dilutive equity offerings (Editas, Assembly Biosciences) or high-cost debt (LiqTech, Future FinTech). Insider activity, where observable, is mixed, but the pattern of repeated debt extensions (Odyssey Health) and governance changes to centralize control (Motorsport Games) are clear red flags for equity holders. The forward-looking data reveals a catalyst-rich calendar, with several Phase 3 clinical trial readouts (Cartesian, Editas) and transformative M&A closings (Allied Gaming, Northern Oil & Gas) that will define the next quarter's winners and losers.

42 high priority 42 total filings
· daily

US Executive Officer Management Changes SEC — May 26, 2026

Today's digest covers 34 filings, revealing a marked uptick in C-suite departures as 2026 progresses, with executive churn concentrated in technology and financial services. Notable insider changes include a co-CEO transition at Dropbox, COO exits at Groupon and CG Oncology, and a new CFO appointment at Peloton Interactive. While several companies—such as Palomar Holdings, Core Scientific, and S&P Global—are strengthening boards with seasoned leaders to advance AI and infrastructure strategies, material period-over-period comparisons are largely absent from these SEC reports, limiting trend-based analysis. Key themes emerge: a wave of insider departures driven by corporate restructuring (Groupon, BILL Holdings) and personal reasons, alongside board refreshes and equity plan expansions that signal long-term alignment. The most actionable insights come from guidance revisions (Groupon raising Adj. EBITDA by ~$5M), CEO promotions with significant compensation increases (Medifast), and high shareholder dissent levels at several annual meetings (Stoneridge, APA Corp, NorthEast Community Bancorp), suggesting governance friction that could influence stock performance.

34 high priority 34 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — May 26, 2026

The single filing processed on May 26, 2026, for Trinseo PLC represents a final-stage corporate distress event: a prepackaged Chapter 11 filing. While the filing lacks comparative period metrics for Trinseo itself, the decisive nature of the action—supported by a supermajority of debt holders—signals a clean, creditor-led restructuring. The key development is the planned elimination of approximately $2.0 billion in debt and a roughly $140 million annual interest expense reduction, drastically reshaping the capital structure. However, the explicit confirmation that existing equity will receive no recovery makes this a watershed moment for shareholders, effectively zeroing out the current equity value. The market implication is bifurcated: debt holders are positioned for a controlled recovery, while common equity is rendered worthless. The filing's high materiality score (10/10) and negative sentiment underscore the total loss for equity investors and highlight the speculative risk of trading stock during proceedings.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 26, 2026

The 34 filings from May 26, 2026, reveal a significant wave of board and C-suite turnover across sectors, with a notable emphasis on AI-driven transformations and digital infrastructure. Key themes include a push for AI-native business models (Groupon, BILL Holdings, S&P Global), strategic board appointments with deep operational and financial expertise (Palomar Holdings, Core Scientific, McCormick), and a series of executive departures and retirements (UFP Technologies, SS Innovations, CVB Financial, Edgewell Personal Care). While most board elections saw strong support, notable dissent emerged at Stoneridge (25.5% against executive compensation) and NorthEast Community Bancorp (22.6% withheld for a director). Period-over-period data was sparse in these filings, but forward-looking statements indicate a focus on growth strategies like 'Palomar 2X' and cost restructuring at Groupon, which raised its Adjusted EBITDA guidance. Insider activity was minimal, but the high volume of senior-level changes signals a period of strategic repositioning across the market.

34 high priority 34 total filings
· daily

US Merger & Acquisition SEC Filings — May 26, 2026

The May 26, 2026, US M&A filings reveal a bifurcated SPAC landscape: two high-stakes quantum computing deals (Bleichroeder/Pasqal and Axiom/Terra Quantum) signal a sector pivot toward next-gen computing, while two other SPACs (Mountain Lake and Rising Dragon) face deal uncertainty or extension pressures. Columbus Acquisition Corp's dual Nasdaq deficiency notices underscore regulatory risk for smaller SPACs, contrasting with BurTech Acquisition Corp II's successful $80M IPO. The ESG Inc. split-off and NL Industries' reincorporation highlight corporate simplification trends. Period-over-period data shows Pasqal's commercial revenue of €16.5M (2025) and booked business of €66M+ indicate strong pre-deal momentum, while CPRO's $326M enterprise value in the Lakeshore deal reflects a premium for AI-integrated security. Insider activity is sparse but notable: no insider transactions were reported across filings, suggesting management is waiting for deal clarity. Forward-looking guidance points to Q4 2026 closings for Lakeshore/CPRO and a 2029 qubit roadmap for Pasqal, creating a catalyst calendar. Overall, the stream signals a 'show me the deal' environment where execution risk is high but rewards are substantial for successful combinations.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 26, 2026

This morning's 50 filings reveal a market bifurcated between aggressive capital deployment (M&A, buybacks, debt issuance) and significant financial distress (going concern warnings, Nasdaq non-compliance, restatements). Key period-over-period trends show revenue growth is often masking margin compression, with CSW Industrials (+23.3% revenue) and AutoZone (+8.4% revenue) both reporting declining operating margins (-490 bps and -57 bps respectively). The most critical developments include GameStop's unsolicited $125/share bid for eBay, Cumberland Pharmaceuticals' $100M asset sale to Apotex, and NOG's $259M strategic entry into Canadian Duvernay Shale. Portfolio-level patterns show a surge in SPAC deal uncertainty (Mountain Lake), biotech regulatory catalysts (Outlook Therapeutics, Editas Medicine), and a wave of IPO filings (Quantinuum, Applied Aerospace, INNIO) signaling robust equity capital markets activity. However, the high number of going concern warnings (TransCode, Global Interactive, Veritone) and restatements (Specificity) demand careful risk management.

21 high priority 29 medium 50 total filings
· daily

Global High-Priority Regulatory Events — May 25, 2026

The May 25, 2026, filing batch reveals a market bifurcated between aggressive capital return programs and deepening corporate distress. A clear cluster of mid-cap companies—CMS Info Systems, Gandhi Special Tubes, and Welspun Living—are deploying significant capital via buybacks, signaling strong balance sheets and management confidence, with buyback sizes ranging from 3% to 7.14% of paid-up capital. Conversely, a wave of insolvency filings (KSS Ltd, Quadrant Televentures, VXL Instruments, BIL Vyapar, Compuage Infocom) highlights ongoing stress in the industrial and telecom sectors, with several companies in advanced CIRP stages (10th-12th CoC meetings). A notable trend is the surge in open offers and delisting proposals, including Lippi Systems (25.05% at ₹56.84) and Shantai Industries (25.60% at ₹21), alongside voluntary delistings at Ras Resorts and Hitech Corporation, suggesting a potential wave of public-to-private transitions. Period-over-period data from Godavari Biorefineries shows a mixed picture: strong FY26 growth (revenue +6% YoY, EBITDA +15.8%) but a sharp Q4 slowdown (revenue -2.7% YoY, EBITDA -24.3% YoY), highlighting a deceleration in the sugar/ethanol segment. The most critical development is the Apollo Hospitals scheme of arrangement, which could reshape the healthcare landscape, while the Jagsonpal buyback (oversubscribed 3.67x) and simultaneous possession notice from Phoenix ARC create a conflicting signal of financial health versus credit recovery action.

34 high priority 34 total filings
· daily

Defense Manufacturing Contracts — May 23, 2026

This digest covers a single, high-value $208.4 million defense-related contract awarded to Textron Aviation Inc. (a subsidiary of Textron Inc.) by the Department of Transportation/FAA. The contract is a firm-fixed-price delivery order for modified King Air 360ER aircraft, awarded without competition, signaling a strong sole-source position for Textron in specialized government aviation. The civilian agency context (FAA) differentiates this from typical DOD procurement, but the aircraft's likely mission (flight inspection, surveillance) ties it to defense-related infrastructure. The highest-conviction signal is Textron's competitive moat in this niche, though the lack of competition introduces protest risk and the zero outlays to date warrant monitoring for execution delays.

1 total filings
· daily

New Federal Contractors — May 23, 2026

The two contracts analyzed total $346.2 million in obligations, split evenly between defense and civilian agencies. The dominant theme is civilian agency procurement of specialized aircraft and IT services, with the FAA’s $208.4 million sole-source award to Textron Aviation for modified King Air 360ER aircraft representing the highest-conviction signal—a non-competitive, fixed-price win that provides predictable revenue. However, the Booz Allen Hamilton $137.8 million GSA FEDSIM contract carries a neutral signal due to its cost-plus pricing structure and an anomalous negative outlay, limiting margin upside. Key risk: the Booz Allen contract’s negative outlay requires clarification, and the Textron award faces potential protest or delay risk given its sole-source nature.

2 total filings